Addex Therapeutics to Conduct Clinical Study of Dipraglurant in Cervical Dystonia

Important Study Examines Oral Medication Therapy


Years of collaboration between the DMRF and Addex Therapeutics have resulted in the announcement of a clinical trial to test a potential dystonia therapy. Addex will conduct a Phase IIa Proof of Concept Study of dipraglurant in focal cervical dystonia. Addex expects to initiate the trial in late 2016.  The study was developed with support from the DMRF and in collaboration with investigators from the Dystonia Coalition, an international network of experts devoted to advancing research in dystonia. H. A. Jinnah, MD, PhD, Director of the Dystonia Coalition and Professor of Neurology at Emory University, will serve as the lead investigator.  

“We are extremely pleased that Addex decided to conduct this trial,” said Jan Teller, PhD, Chief Scientific Officer of the DMRF. “This places Addex among a few pioneering pharmaceutical companies who attempt to develop new oral treatments for dystonia patients. Our Foundation will continue to support these efforts in any way possible.”

Cervical dystonia, affecting the neck and shoulder muscles, is the most prevalent form of dystonia, occurring in approximately 50,000 patients in the United States. Treating cervical dystonia can be challenging, and available therapies, such as oral medications and botulinum neurotoxin injections, do not provide adequate or consistent benefit for all patients. Addex’s study will include a sample of cervical dystonia patients for whom botulinum neurotoxin injections do not provide optimal relief.  The single center study will be double-blinded and placebo-controlled.  

“We are excited to be moving dipraglurant for focal cervical dystonia forward in the clinic,” said Tim Dyer, CEO of Addex. “We are pleased to have Professor Jinnah, a world-renowned neurology expert, serving as lead investigator for our study, and are grateful for the continued support from the Dystonia Medical Research Foundation.”

Dipraglurant, a novel small molecule inhibitor of the metabotropic glutamate receptor 5, has demonstrated positive dystonia-reducing effects in multiple animal models of dystonia. The drug has also has shown promise in the treatment of levodopa-induced dyskinesia and dystonia in Parkinson's disease.

The DMRF will share additional details about this study as updates are available.

Accelerating Research & Inspiring Hope

The Dystonia Medical Research Foundation (DMRF) has served the dystonia community since 1976. Join us in our global effort to find a cure.